DE69708919D1 - Neue liposomkomplexe mit erhöhter systemischer verabreichung - Google Patents

Neue liposomkomplexe mit erhöhter systemischer verabreichung

Info

Publication number
DE69708919D1
DE69708919D1 DE69708919T DE69708919T DE69708919D1 DE 69708919 D1 DE69708919 D1 DE 69708919D1 DE 69708919 T DE69708919 T DE 69708919T DE 69708919 T DE69708919 T DE 69708919T DE 69708919 D1 DE69708919 D1 DE 69708919D1
Authority
DE
Germany
Prior art keywords
liposomes
expression
highly efficient
liposome complexes
systemic administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69708919T
Other languages
English (en)
Other versions
DE69708919T2 (de
Inventor
Nancy Smyth-Templeton
N Pavlakis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institutes of Health NIH
Original Assignee
National Institutes of Health NIH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institutes of Health NIH filed Critical National Institutes of Health NIH
Publication of DE69708919D1 publication Critical patent/DE69708919D1/de
Application granted granted Critical
Publication of DE69708919T2 publication Critical patent/DE69708919T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Medical Informatics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
DE69708919T 1996-08-19 1997-08-01 Neue liposomkomplexe mit erhöhter systemischer verabreichung Expired - Lifetime DE69708919T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2438696P 1996-08-19 1996-08-19
PCT/US1997/013599 WO1998007408A1 (en) 1996-08-19 1997-08-01 Novel liposome complexes for increased systemic delivery

Publications (2)

Publication Number Publication Date
DE69708919D1 true DE69708919D1 (de) 2002-01-17
DE69708919T2 DE69708919T2 (de) 2002-06-27

Family

ID=21820321

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69708919T Expired - Lifetime DE69708919T2 (de) 1996-08-19 1997-08-01 Neue liposomkomplexe mit erhöhter systemischer verabreichung

Country Status (8)

Country Link
US (1) US6413544B1 (de)
EP (1) EP0955999B1 (de)
JP (1) JP4203835B2 (de)
AT (1) ATE209902T1 (de)
AU (1) AU730771B2 (de)
CA (1) CA2263705C (de)
DE (1) DE69708919T2 (de)
WO (1) WO1998007408A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7288266B2 (en) * 1996-08-19 2007-10-30 United States Of America As Represented By The Secretary, Department Of Health And Human Services Liposome complexes for increased systemic delivery
AUPQ002399A0 (en) * 1999-04-28 1999-05-20 Australian National University, The Model membrane systems
EP1180016B1 (de) * 1999-05-24 2006-09-27 Introgen Therapeutics, Inc. Verfahren und zusammensetzungen für nichtvirale gentherapie zur behandlung von hyperproliferativen krankheiten
EP1754488A1 (de) 1999-05-24 2007-02-21 Introgen Therapeutics, Inc. Verfahren und Zusammensetzungen für nichtvirale Gentherapie zur Behandlung von hyperproliferativen Krankheiten
TR199901199A3 (tr) * 1999-05-31 2001-09-21 Kocagoez Tanil Bakteri transformasyon kiti
AUPQ259399A0 (en) 1999-09-01 1999-09-23 Lustre Investments Pte Ltd Therapeutic agents
US10293056B1 (en) * 2000-05-24 2019-05-21 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
US6477426B1 (en) * 2000-06-20 2002-11-05 Celsion Corporation System and method for heating the prostate gland to treat and prevent the growth and spread of prostate tumors
US7037520B2 (en) 2002-03-22 2006-05-02 Baylor College Of Medicine Reversible masking of liposomal complexes for targeted delivery
US20040082521A1 (en) * 2002-03-29 2004-04-29 Azaya Therapeutics Inc. Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases
US20060003316A1 (en) * 2002-07-15 2006-01-05 John Simard Immunogenic compositions derived from poxviruses and methods of using same
US20040048260A1 (en) * 2002-09-10 2004-03-11 Fu-Hsiung Chang Transfection of nucleic acid
AU2003287526A1 (en) * 2002-11-06 2004-06-03 Protein-stabilized liposomal formulations of pharmaceutical agents
WO2004104032A2 (en) 2003-05-14 2004-12-02 The University Of Iowa Research Foundation Methods and compositions related to high-titer pseudotyped retroviruses
US8034790B2 (en) 2003-12-01 2011-10-11 Introgen Therapeutics Use of MDA-7 to inhibit pathogenic infectious organisms
JP5266433B2 (ja) * 2004-03-19 2013-08-21 ロードス ビオターゲット ゲーエムベーハー Ctl/ctldの細胞炭水化物認識ドメインへターゲティングするための炭水化物誘導体化リポソーム、および治療的に活性な化合物の細胞内送達
WO2007149062A2 (en) * 2005-03-14 2007-12-27 Board Of Regents, The University Of Texas System Bioactive fus1 peptides and nanoprticle-polypeptide complexes
EP1867726A4 (de) * 2005-03-24 2008-09-24 Univ Hokkaido Nat Univ Corp Zur wirksamen zuführung einer gegebenen substanz in den zellkern fähiges liposom
EP1940355B1 (de) 2005-09-30 2012-12-19 Auburn University Nanoträger zur gezielten Freisetzung eines Wirkstoffs - enthaltend Ansammlungen von auf ein Ziel ausgerichteten Landschaftsphagenproteinen
WO2007100465A2 (en) 2006-02-10 2007-09-07 The University Of Cincinnati Phosphatase inhibitor protein-1 as a regulator of cardiac function
US20070274908A1 (en) 2006-04-07 2007-11-29 The Board Of Regents Of The University Of Texas System Methods and compositions related to adenoassociated virus-phage particles
WO2008077413A1 (es) 2006-12-22 2008-07-03 Soluciones Biotecnologicas Innovacion Ltda Vacunas adn en peces
JP5415283B2 (ja) * 2007-02-07 2014-02-12 グラダリス インク. シアル酸産生を調節し、遺伝性封入体ミオパチーを治療する方法及び組成物
US9446150B2 (en) 2007-10-09 2016-09-20 Washington University Particles for imaging
WO2009049089A1 (en) * 2007-10-09 2009-04-16 Washington University In St. Louis Ligand directed toroidal nanoparticles for therapy and diagnostic imaging
PL2245464T3 (pl) 2008-01-25 2017-08-31 Multivir Inc. Biomarkery p53
US8563690B2 (en) * 2008-11-03 2013-10-22 The Board Of Trustees Of The University Of Illinois Modulation of platelet aggregation
US9409983B2 (en) 2009-07-23 2016-08-09 The Board Of Trustess Of The University Of Illinois Methods and compositions involving PBEF inhibitors for lung inflammation conditions and diseases
US9808500B2 (en) 2009-12-17 2017-11-07 Washington University Antithrombotic nanoparticle
US9764043B2 (en) 2009-12-17 2017-09-19 Washington University Antithrombotic nanoparticle
AU2011239414A1 (en) 2010-04-15 2012-11-08 The Washington University Prodrug compositions, prodrug nanoparticles, and methods of use thereof
CN103201293B (zh) 2010-09-08 2016-04-27 哈洛齐梅公司 评估和鉴定或发展条件活性治疗蛋白的方法
ES2634669T3 (es) 2011-02-08 2017-09-28 Halozyme, Inc. Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata
WO2012119095A1 (en) 2011-03-02 2012-09-07 Board Of Regents, The University Of Texas System Fus1/tusc2 therapies
US10040853B2 (en) 2011-09-09 2018-08-07 Fred Hutchinson Cancer Research Center Methods and compositions involving NKG2D inhibitors and cancer
NZ630020A (en) 2012-03-08 2016-08-26 Halozyme Inc Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
CN110464709A (zh) 2012-08-10 2019-11-19 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
MX2016009771A (es) 2014-01-31 2016-11-14 Factor Bioscience Inc Metodos y productos para la produccion y administracion de acido nucleico.
JP7199809B2 (ja) 2015-02-13 2023-01-06 ファクター バイオサイエンス インコーポレイテッド 核酸製品及びその投与方法
EP3808340A1 (de) * 2015-09-18 2021-04-21 Dnarx Systeme und verfahren zur in-vivo-nukleinsäureexpression
ES2892972T3 (es) 2015-11-02 2022-02-07 Univ Texas Métodos de activación de CD40 y bloqueo de punto de control inmunitario
CN108884159A (zh) 2015-11-07 2018-11-23 茂体外尔公司 用于癌症治疗的包含肿瘤抑制基因治疗和免疫检查点阻断的组合物
WO2017216775A2 (en) 2016-06-16 2017-12-21 The Regents Of The University Of California Identification of factor that promotes human hsc self-renewal
CA3029582A1 (en) 2016-07-01 2018-01-04 Research Development Foundation Elimination of proliferating cells from stem cell-derived grafts
IL264439B1 (en) 2016-08-17 2024-04-01 Factor Bioscience Inc A suitable viral preparation containing a synthetic messenger RNA encoding a gene editing protein for use in cancer treatment and a synthetic messenger RNA encoding a gene editing protein for use in therapy
CN116672456A (zh) 2016-10-12 2023-09-01 得克萨斯州大学系统董事会 用于tusc2免疫治疗的方法和组合物
CA3046961A1 (en) 2016-12-12 2018-06-21 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
JP2020511521A (ja) * 2017-03-23 2020-04-16 ディーエヌエーアールエックス in vivoでの核酸発現のためのシステム及び方法
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
KR20200135986A (ko) 2018-03-19 2020-12-04 멀티비르 인코포레이티드 종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물
WO2019209956A1 (en) * 2018-04-25 2019-10-31 University Of Massachusetts Artificial exosome composition and related methods
CN108653750B (zh) * 2018-06-01 2022-04-22 成都诺恩基因科技有限公司 包裹质粒dna的阳离子脂质体复合物
US11733242B2 (en) 2018-10-31 2023-08-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Biomarkers and methods of use for radiation-induced lung injury
KR20220061977A (ko) 2019-08-12 2022-05-13 퓨리노미아 바이오테크, 아이엔씨. Cd39 발현 세포의 adcc 표적화를 통해 t 세포 매개 면역 반응을 촉진 및 강화하기 위한 방법 및 조성물
TW202128775A (zh) 2019-10-16 2021-08-01 英商阿法克塔生命科學有限公司 PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
TW202332694A (zh) 2021-10-07 2023-08-16 英商阿凡克塔生命科學公司 血清半衰期延長之pd-l1結合多肽
TW202334196A (zh) 2021-10-07 2023-09-01 英商阿法克塔生命科學有限公司 Pd-l1結合多肽
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5206027A (en) * 1990-09-13 1993-04-27 Fuji Photo Film Co., Ltd. Amphipathic compound and liposome comprising the same
CA2134773A1 (en) * 1992-06-04 1993-12-09 Robert J. Debs Methods and compositions for in vivo gene therapy

Also Published As

Publication number Publication date
JP2000516630A (ja) 2000-12-12
US20020028219A1 (en) 2002-03-07
EP0955999B1 (de) 2001-12-05
CA2263705C (en) 2007-12-04
DE69708919T2 (de) 2002-06-27
US6413544B1 (en) 2002-07-02
AU4050297A (en) 1998-03-06
JP4203835B2 (ja) 2009-01-07
EP0955999A1 (de) 1999-11-17
CA2263705A1 (en) 1998-02-26
WO1998007408A1 (en) 1998-02-26
ATE209902T1 (de) 2001-12-15
AU730771B2 (en) 2001-03-15

Similar Documents

Publication Publication Date Title
DE69708919D1 (de) Neue liposomkomplexe mit erhöhter systemischer verabreichung
Kawakami et al. Asialoglycoprotein receptor-mediated gene transfer using novel galactosylated cationic liposomes
DE69906977D1 (de) In liposomen verkapselte nukleinsäurekomplexe
CA2270396A1 (en) Cationic reagents for transfection
EP0759694A4 (de) Verfahren zur in-vivo abgabe therapeutischer agenzien mittels liposomen
DE69837819D1 (de) Kondensierte plasmid-liposome komplex zur transfektion
Loughrey et al. A non-covalent method of attaching antibodies to liposomes
ATE172636T1 (de) Liposomales verabreichungssystem für biologisch aktive stoffe
IL130823A0 (en) Peptide-lipid conjugates liposomes and liposomal drug delivery
ATE273320T1 (de) Fusogene liposomen
WO1997011682A3 (en) Emulsion and micellar formulations for the delivery of biologically active substances to cells
FI963103A (fi) Ei-virusvektori
AU1724097A (en) Lipids and their use, for example, in liposomes
CA2219119A1 (en) Nucleic acid ligand complexes
ATE322255T1 (de) Polyamid-oligomere
DE69830249D1 (de) Zielgerichtete liposomen zur verabreichung von genen
AU1776801A (en) Modular targeted liposomal delivery system
WO1999059643A3 (en) Liposomal delivery complex
EE200000102A (et) Meetodid ja kompositsioonid teraapiaks, kasutades sekreteeritavaid valke, näiteks interferoon-beetat kodeerivaid geene
WO1999065461A3 (en) Cationic amphiphile micellar complexes
ATE359764T1 (de) Durch liposome vermittelte dna verabreichung
CO5280052A1 (es) Virosomas cationicos dosper
MX9708111A (es) Lipidos cationicos para terapia genica.
CA2051439A1 (en) Liposomal targeting of ischemic tissue

Legal Events

Date Code Title Description
8364 No opposition during term of opposition